blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3194624

EP3194624 - METHODS FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF BREAST CANCER AND REAGENTS THEREFOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.12.2022
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  14.01.2022
FormerGrant of patent is intended
Status updated on  16.09.2021
FormerExamination is in progress
Status updated on  06.09.2019
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  08.04.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst, NSW 2010 / AU
[2022/07]
Former [2017/30]For all designated states
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst, NSW 2010 / AU
Inventor(s)01 / CLARK, Susan
41 Bellevue Street
Chatswood, New South Wales 2067 / AU
02 / ZOTENKO, Elena
73/3 Foy Street
Balmain, New South Wales 2041 / AU
03 / STIRZAKER, Clare
11 Chelmsford Avenue
Lindfield, New South Wales 2070 / AU
04 / FRANCIS, Glenn
9 Pebble Creek Road
Bonogin, Queensland 4213 / AU
 [2017/30]
Representative(s)Myint, Julie Marie, et al
Symbiosis IP Limited
Cardiff MediCentre
Heath Park
Cardiff CF14 4UJ / GB
[2022/07]
Former [2017/30]Lee, Nicholas John, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date15841542.215.09.2015
[2017/30]
WO2015AU50549
Priority number, dateAU2014090368015.09.2014         Original published format: AU 2014903680
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016041010
Date:24.03.2016
Language:EN
[2016/12]
Type: A1 Application with search report 
No.:EP3194624
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.03.2016 takes the place of the publication of the European patent application.
[2017/30]
Type: B1 Patent specification 
No.:EP3194624
Date:16.02.2022
Language:EN
[2022/07]
Search report(s)International search report - published on:AU24.03.2016
(Supplementary) European search report - dispatched on:EP27.07.2018
ClassificationIPC:C12Q1/6886
[2021/37]
CPC:
C12Q1/6886 (EP,US); C12Q2600/106 (EP,US); C12Q2600/118 (EP,US);
C12Q2600/154 (EP,US)
Former IPC [2017/30]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:VERFAHREN ZUR DIAGNOSE, PROGNOSE UND ÜBERWACHUNG VON BRUSTKREBS UND REAGENZIEN DAFÜR[2017/30]
English:METHODS FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF BREAST CANCER AND REAGENTS THEREFOR[2017/30]
French:MÉTHODES POUR LE DIAGNOSTIC, LE PRONOSTIC ET LA SURVEILLANCE DU CANCER DU SEIN ET RÉACTIFS CORRESPONDANTS[2017/30]
Entry into regional phase07.04.2017National basic fee paid 
07.04.2017Search fee paid 
07.04.2017Designation fee(s) paid 
07.04.2017Examination fee paid 
Examination procedure07.04.2017Examination requested  [2017/30]
07.04.2017Date on which the examining division has become responsible
16.01.2019Amendment by applicant (claims and/or description)
10.09.2019Despatch of a communication from the examining division (Time limit: M06)
06.03.2020Reply to a communication from the examining division
17.07.2020Despatch of a communication from the examining division (Time limit: M04)
10.11.2020Reply to a communication from the examining division
17.09.2021Communication of intention to grant the patent
11.01.2022Fee for grant paid
11.01.2022Fee for publishing/printing paid
11.01.2022Receipt of the translation of the claim(s)
Opposition(s)17.11.2022No opposition filed within time limit [2023/04]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
19.07.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
14.09.2020Renewal fee patent year 06
10.09.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
MK16.02.2022
MT16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
TR16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
[2024/41]
Former [2024/29]HU15.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
MK16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
TR16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2024/27]HU15.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
MK16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2024/21]HU15.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2024/18]HU15.09.2015
AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/42]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/35]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/33]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
IE15.09.2022
LU15.09.2022
Former [2023/30]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
LU15.09.2022
Former [2023/22]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2023/10]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2023/01]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/49]AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/48]AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/47]AT16.02.2022
DK16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/46]AT16.02.2022
DK16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/42]AT16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
IS17.06.2022
Former [2022/39]AT16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
Former [2022/36]AT16.02.2022
ES16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
Former [2022/35]ES16.02.2022
HR16.02.2022
LT16.02.2022
NL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
PT16.06.2022
Former [2022/34]ES16.02.2022
LT16.02.2022
NL16.02.2022
NO16.05.2022
PT16.06.2022
Former [2022/33]LT16.02.2022
NO16.05.2022
Documents cited:Search[XA]WO02059347  (UNIV JOHNS HOPKINS MED [US]) [X] 11-15 * pages 29-36; example 1; claims 1-3, 16 * [A] 1-10;
 [X]WO2004044123  (ROSETTA GENOMICS LTD [IL], et al) [X] 11-15* sequence 228624 *;
 [A]EP1942197  (EPIGENOMICS AG [DE]) [A] 1-3,9-15 * claim 1; sequence 32556 *;
 [X]WO2010150103  (UNIV STRASBOURG [FR], et al) [X] 11-15 * sequence 8 *;
 [I]WO2012038837  (STICHTING NL KANKER INST [NL], et al) [I] 1-3,9-15 * paragraphs [0183] , [0203] - [0206]; example 2; table 6 *;
 [XA]US2012184455  (FOEKENS JOHN [NL], et al) [X] 11-15 * item 8; page 18; table 1 * [A] 4-10;
 [I]WO2012129352  (UNIV YALE [US], et al) [I] 1-3,9-15 * paragraph [0294]; claim 45; table 16 *;
 [I]  - M T BRANHAM ET AL, "Methylation profile of triple-negative breast carcinomas", ONCOGENESIS, (20120701), vol. 1, no. 7, doi:10.1038/oncsis.2012.17, page e17, XP055418616 [I] 1-3,9-15 * abstract *

DOI:   http://dx.doi.org/10.1038/oncsis.2012.17
 [I]  - PRIYANKA SHARMA ET AL, "The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer", JOURNAL OF CANCER THERAPEUTICS AND RESEARCH, (20140101), vol. 3, no. 1, doi:10.7243/2049-7962-3-2, pages 1 - 11, XP055418630 [I] 1-3,9-15 * abstract *

DOI:   http://dx.doi.org/10.7243/2049-7962-3-2
 [X]  - Ncbi, "Homo sapiens chromosome 8 open reading frame 88 (C8orf88), mRNA - NCBI Reference Sequence: NM_001190972.1", (20140227), URL: https://www.ncbi.nlm.nih.gov/nuccore/302318879?sat=21&satkey=4818115, (20180309), XP055458048 [X] 11-15 * the whole document *
 [XA]  - LUCIANO CASCIONE ET AL, "Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer", PLOS ONE, (20130206), vol. 8, no. 2, doi:10.1371/journal.pone.0055910, page e55910, XP055165763 [X] 11-15 * the whole document * [A] 4-10

DOI:   http://dx.doi.org/10.1371/journal.pone.0055910
 [XA]  - MASANORI KANEUCHI ET AL, "WT1 andWT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma", CANCER., US, (20051101), vol. 104, no. 9, doi:10.1002/cncr.21397, ISSN 0008-543X, pages 1924 - 1930, XP055491400 [X] 11-15 * the whole document * [A] 4-10

DOI:   http://dx.doi.org/10.1002/cncr.21397
 [XA]  - MIYOSHI Y ET AL, "High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20020501), vol. 8, no. 5, ISSN 1078-0432, pages 1167 - 1171, XP002373767 [X] 11-15 * abstract * * page 1170, column 2, paragraph 2 * [A] 4-10
 [XA]  - ROBERT KORNEGOOR ET AL, "Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD, GB, (20120705), vol. 14, no. 4, doi:10.1186/BCR3220, ISSN 1465-5411, page R101, XP021127722 [X] 11-15 * abstract * [A] 4-10

DOI:   http://dx.doi.org/10.1186/bcr3220
 [XA]  - LOEB D M ET AL, "Wilm's tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20010201), vol. 61, ISSN 0008-5472, pages 921 - 925, XP002963863 [X] 11-15 * abstract * [A] 4-10
 [XA]  - DIEGO M. MARZESE ET AL, "DNA Methylation Index and Methylation Profile of Invasive Ductal Breast Tumors", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, US, (20121101), vol. 14, no. 6, doi:10.1016/j.jmoldx.2012.07.001, ISSN 1525-1578, pages 613 - 622, XP055491544 [X] 11-15 * abstract * * page 617, column 1, paragraph 3 - page 619, column 2, paragraph 2 * [A] 4-10

DOI:   http://dx.doi.org/10.1016/j.jmoldx.2012.07.001
 [XA]  - CATHY B MOELANS ET AL, "Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer", THE JOURNAL OF PATHOLOGY, (20111001), vol. 225, no. 2, doi:10.1002/path.2930, ISSN 0022-3417, pages 222 - 231, XP055491415 [X] 11-15 * the whole document * [A] 4-10

DOI:   http://dx.doi.org/10.1002/path.2930
 [XA]  - TOMASZ K WOJDACZ ET AL, "Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD, GB, (20140203), vol. 16, no. 1, doi:10.1186/BCR3612, ISSN 1465-5411, page R17, XP021179705 [X] 11-15 * abstract * [A] 4-10

DOI:   http://dx.doi.org/10.1186/bcr3612
 [XA]  - DOUGLAS E LAUX ET AL, "Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (19990701), vol. 56, no. 1, ISSN 1573-7217, pages 35 - 43, XP019274516 [X] 11-15 * abstract * [A] 4-10
 [XA]  - EMANUEL MARTÍN CAMPOY ET AL, "Aberrant DNA Methylation in Breast Cancer Cells", MEDICAL EPIGENETICS, (20130101), vol. 1, no. 1, doi:10.1159/000355616, pages 88 - 92, XP055491409 [X] 11-15 * the whole document * [A] 4-10

DOI:   http://dx.doi.org/10.1159/000355616
 [XA]  - ZE-GUANG HAN ET AL, "Molecular Cloning of Six Novel Krüppel -like Zinc Finger Genes from Hematopoietic Cells and Identification of a Novel Transregulatory Domain KRNB", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (19991210), vol. 274, no. 50, doi:10.1074/jbc.274.50.35741, ISSN 0021-9258, pages 35741 - 35748, XP055491706 [X] 11-15 * the whole document * [A] 4-10

DOI:   http://dx.doi.org/10.1074/jbc.274.50.35741
 [P]  - "Sequence 228624 from Patent EP1572962.", EMBL, (20150617), Database accession no. JD247600, URL: EBI [P] * sequence . *
International search[XA]WO0106005  (UNIV BRISTOL [GB], et al) [X] 23-27, 32-35 * Abstract; page 10, last paragraph; Figure 1; page 7, last paragraph; claims 20, 35 * [A] 1-22, 23-31;
 [L]WO2012098215  (UNIV BRUXELLES [BE], et al) [L] 0 * Lack of Unity *;
 [A]WO2012106559  (TRANSLATIONAL GENOMICS RES INST [US], et al) [A] 1-35 * Claims; Table 21; para [0071] *;
 [L]WO2013012781  (UNIV JOHNS HOPKINS [US], et al) [L] 0 * Lack of Unity *;
 [A]  - BRANHAM, M. et al., "Methylation profile f triple-negative breast carcinomas", Oncoenesis, (20120000), vol. 1, page e1 7, XP055418616 [A] 1-35 * Abstract; Results; Figures 1 and 2 *

DOI:   http://dx.doi.org/10.1038/oncsis.2012.17
 [A]  - KOWALSKI, J. et al., "Methylation signatures specific to triple negative breast cancer subtypes", Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer, Atlanta, Georgia, USA, (20130619), vol. 73, no. 13, XP055418621 [A] 1-35 * Abstract *

DOI:   http://dx.doi.org/10.1158/1538-7445.CEC13-B40
 [A]  - SHARMA, P. et al., "The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer", Journal of Cancer Therapeutics & Research, (20140319), vol. 3, pages 1 - 11, XP055418630 [A] 1-35 * Abstract; Conclusions *

DOI:   http://dx.doi.org/10.7243/2049-7962-3-2
 [PX]  - STIRZAKER, C. et al., "Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value", Nature Communications, (20150202), vol. 6, no. 5899, XP055418632 [PX] 1-35 * The Entire Document *

DOI:   http://dx.doi.org/10.1038/ncomms6899
by applicantUS4492762
 US4593089
 US4668640
 US4751190
 EP0320308
 US4847209
 US4883750
 US5143854
 WO9617958
 US5571728
 WO9849557
 US5837832
 US6174670
 WO0106005
 US6248597
 US6306610
 US6514770
 WO03072810
 US2004228761
 US2004248322
 US2004265926
    - NARANG et al., Meth. Enzymol, (19790000), vol. 68, page 90
    - BEAUCAGE et al., Tetrahedron Letters, (19810000), vol. 22, pages 1859 - 1862
    - CARUTHERS, M. H. et al., Methods in Enzymology, (19880000), vol. 154, pages 287 - 314
    - NIELSEN et al., J. Chem. Soc. Perkin Trans., (19970000), vol. 1, page 3423
    - SINGHWENGEL, Chem. Commun., (19980000), page 1247
    - EGHOLM et al., Am. Chem. Soc., (19920000), vol. 114, page 1895
    - EGHOLM et al., Nature, (19930000), vol. 365, page 566
    - ORUM et al., Nucl. Acids Res., (19930000), vol. 21, page 5332
    - KAWAI et al., Mol. Cell. Biol., (19940000), vol. 14, pages 7421 - 7427
    - GONZALGO et al., Cancer Res, (19970000), vol. 57, pages 594 - 599
    - FROMMER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 93, pages 9821 - 9826
    - SINGER-SAM et al., Nucl. Acids Res., (19900000), vol. 18, page 687
    - FODOR et al., Science, (19910000), pages 767 - 773
    - SZABOMANN, Genes Dev, (19950000), vol. 9, pages 3097 - 3108
    - CLARK et al., Nucl. Acids Res., (19940000), vol. 22, pages 2990 - 2997
    - UHLMANN et al., Electrophoresis, (20020000), vol. 23, pages 4072 - 4079
    - GONZALGOJONES, Nucl. Acids Res., (20010000), vol. 25, pages 2532 - 2534
    - SYVAMEN et al., Genomics, (19920000), vol. 13, pages 1008 - 1017
    - CHENKWOK, Nucleic Acids Res., (19970000), vol. 25, pages 347 - 353
    - GONZALGO et al., Cancer Res., (19970000), vol. 57, pages 594 - 599
    - ADORJAN et al., Nucl. Acids Res., (20020000), vol. 30, page e21
    - KUPPUSWAMY et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, pages 1143 - 1147
    - SINGER-SAM et al., PCR Methods Appl, (19920000), vol. 1, pages 160 - 163
    - WORM et al., Clin. Chem., (20010000), vol. 47, pages 1183 - 1189
    - HOLLAND et al., Proc. Natl Acad. Sci. USA, (19910000), vol. 88, pages 7276 - 7280
    - LEE et al., Nucleic Acid Res., (19930000), vol. 21, pages 3761 - 3766
    - EADS et al., Nucl. Acids Res, (20000000), vol. 28, page E32
    - MHLANGMALMBERG, Methods, (20010000), vol. 25, pages 463 - 471
    - BIANCO et al., Hum. Mutat., (19990000), vol. 14, pages 289 - 293
    - ABRAMSSTANTON, Methods Enzymol., (19920000), vol. 212, pages 71 - 74
    - DENG et al., Chin. J. Cancer Res., (20000000), vol. 12, pages 171 - 191
    - HSU et al., Methods Mol Biol, (20140000), vol. 1105, pages 61 - 70
    - SERRE et al., Nucleic Acids Res, (20100000), vol. 38, pages 391 - 399
    - RAUCHPFEIFER, Lab Invest, (20050000), vol. 85, pages 1172 - 1180
    - NAIR et al., Epigenetics, (20110000), vol. 6, pages 34 - 44
    - ROBINSON et al., Genome Res, (20100000), vol. 20, pages 1719 - 1729
    - LEE et al., Proteomics, (20030000), vol. 3, pages 2289 - 2304
    - PAVLICKOVA et al., Biotechniques, (20030000), vol. 34, pages 124 - 130
    - ARENKOV et al., Anal. Biochem., (20000000), vol. 278, pages 123 - 131
    - PEROU et al., Nature, (20000000), vol. 406, pages 747 - 752
    - ERNST et al., Nature, (20110000), vol. 473, pages 43 - 49
    - PEROU CM, Oncologist, (20110000), vol. 16, pages 61 - 70
    - BLOWS et al., PLoSMed., (20100000), vol. 7, page el000279
    - JATOI et al., Journal of Clinical Oncology, (20110000), vol. 29, pages 2301 - 2304
    - PARK et al., Annals of Oncology, (20110000), vol. 22, pages 1554 - 1560
    - REIS-FILHOPUSZTAI, The Lancet, (20110000), vol. 378, pages 1812 - 1823
    - Nature, TCGA, (20120000), vol. 490, pages 61 - 70
    - LAIRD PW, Nat. Rev. Cancer, (20030000), vol. 3, pages 253 - 266
    - MEHLEN et al., Nat. Rev. Cancer, (20110000), vol. 11, pages 188 - 197
    - NEUFELDKESSLER, Nat. Rev. Cancer, (20080000), vol. 8, pages 632 - 645
    - YANG et al., Leukemia, (20070000), vol. 21, pages 868 - 876
 WO2002AU01684
 WO2003AU00244
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.